Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.32 |
| ▸ | BHMT | Q93088 | 3/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12438551 | 1.00 | ALDH1A1 (0.54) | ALDH1A1MAPTPTGS1TP53KIF11 | |
| SCHEMBL2875767 | 1.00 | ALDH1A1 (0.54) | ALDH1A1MAPTPTGS1TP53KIF11 | |
| SCHEMBL6234510 | 1.00 | ALDH1A1 (0.54) | ALDH1A1MAPTPTGS1TP53KIF11 | |
| SCHEMBL6501684 | 1.00 | ALDH1A1 (0.54) | ALDH1A1MAPTPTGS1TP53KIF11 | |
| SCHEMBL19371196 | 0.88 | ALDH1A1 (0.48) | ALDH1A1MAPTPTGS1TP53KIF11 | |
| SCHEMBL7876560 | 0.82 | ALDH1A1 (0.52) | ALDH1A1MAPTPTGS1KIF11SLC7A5 | |
| SCHEMBL7418366 | 0.82 | ALDH1A1 (0.52) | ALDH1A1MAPTPTGS1KIF11SLC7A5 | |
| SCHEMBL7184921 | 0.82 | ALDH1A1 (0.52) | ALDH1A1MAPTPTGS1KIF11SLC7A5 | |
| SCHEMBL436388 | 0.80 | PTGS1 (0.56) | ALDH1A1MAPTPTGS1KIF11SLC7A5 | |
| SCHEMBL21443801 | 0.80 | ALDH1A1 (0.50) | ALDH1A1MAPTPTGS1KIF11SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1389743-A1 | Stable photographic color developing composition and method of use | EASTMAN KODAK COMPANY (US) | 2004-02-18 | — | — | EP | claimed |
| US-6623915-B1 | Isomers of cysteine or cystine or a salt thereof are most preferred preservatives | EASTMAN KODAK COMPANY | 2003-09-23 | — | — | US | claimed |
| EP-1191395-A1 | Ascorbic acid developing compositions and methods of use | EASTMAN KODAK COMPANY (US) | 2002-03-27 | — | — | EP | claimed |
| US-20250360158-A1 | OLIGONUCLEOTIDE ANALOGUE FORMULATIONS | NEUBASE THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| CN-110435048-B | Waste rubber track material recycling production line | 镇江市胜得机械制造有限责任公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240132628-A1 | OLIGONUCLEOTIDE ANALOGUE THERAPEUTICS FOR TREATMENT OF NEUROMUSCULAR DISEASE | NEUBASE THERAPEUTICS, INC. | 2024-04-25 | — | — | US | disclosed |
| CN-211030834-U | Waste rubber track material recycling production line | 镇江市胜得机械制造有限责任公司 | 2020-07-17 | — | — | CN | disclosed |
| CN-110435048-A | A kind of waste old track material remanufacture line | ZHENJIANG SHENGDE MACH MFG CO LTD | 2019-11-12 | — | — | CN | disclosed |
| EP-1389743-A1 | Stable photographic color developing composition and method of use | EASTMAN KODAK COMPANY (US) | 2004-02-18 | — | — | EP | disclosed |
| US-6623915-B1 | Isomers of cysteine or cystine or a salt thereof are most preferred preservatives | EASTMAN KODAK COMPANY | 2003-09-23 | — | — | US | disclosed |
| EP-1191395-A1 | Ascorbic acid developing compositions and methods of use | EASTMAN KODAK COMPANY (US) | 2002-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360158-A1 | OLIGONUCLEOTIDE ANALOGUE FORMULATIONS | SNRPA1, SNRPA, SNRPE | ALDH1A1 4761/4885MAPT 1354/4885PTGS1 4733/4885 |
| US-20240132628-A1 | OLIGONUCLEOTIDE ANALOGUE THERAPEUTICS FOR TREATMENT OF NEUROMUSCULAR DISEASE | SMN1; SMN2, POLRMT, TARDBP | ALDH1A1 4168/4885MAPT 966/4885PTGS1 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.